Acadian Asset Management
TEVA icon

Acadian Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Acadian Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Buy
397,716
+316,587
+390% +$10.2M 0.02% 488
2025
Q4 		$2.53M Buy
81,129
+72,226
+811% +$1.78M ﹤0.01% 849
2025
Q3 		$179K Buy
+8,903
New +$156K ﹤0.01% 1419
2024
Q4 		– Sell
-939,248
Closed -$16.9M – 2154
2024
Q3 		$16.9M Sell
939,248
-185,501
-16% -$3.25M 0.05% 256
2024
Q2 		$18.3M Buy
1,124,749
+535,164
+91% +$8.24M 0.06% 248
2024
Q1 		$8.31M Buy
589,585
+379,677
+181% +$4.79M 0.03% 347
2023
Q4 		$2.19M Sell
209,908
-163,394
-44% -$1.53M 0.01% 648
2023
Q3 		$3.81M Buy
373,302
+339,605
+1,008% +$3.16M 0.02% 518
2023
Q2 		$253K Sell
33,697
-93,572
-74% -$759K ﹤0.01% 1220
2023
Q1 		$1.13M Buy
127,269
+123,120
+2,967% +$1.22M ﹤0.01% 850
2022
Q4 		$37K Buy
+4,149
New +$36.2K ﹤0.01% 1624
2022
Q3 		– Sell
-130,170
Closed -$979K – 1842
2022
Q2 		$979K Sell
130,170
-17,059
-12% -$149K 0.01% 823
2022
Q1 		$1.38M Buy
147,229
+74,938
+104% +$625K 0.01% 758
2021
Q4 		$576K Sell
72,291
-6,186
-8% -$55.8K ﹤0.01% 973
2021
Q3 		$764K Buy
78,477
+9,312
+13% +$87.2K ﹤0.01% 926
2021
Q2 		$684K Hold
69,165
– – ﹤0.01% 1042
2021
Q1 		$798K Buy
69,165
+7,883
+13% +$90.4K ﹤0.01% 1025
2020
Q4 		$591K Sell
61,282
-13,054
-18% -$125K ﹤0.01% 1175
2020
Q3 		$669K Buy
+74,336
New +$786K ﹤0.01% 1045
2020
Q1 		– Sell
-419,265
Closed -$4.11M – 1939
2019
Q4 		$4.11M Sell
419,265
-740,453
-64% -$6.61M 0.02% 483
2019
Q3 		$7.98M Sell
1,159,718
-40,417
-3% -$310K 0.03% 382
2019
Q2 		$11.1M Buy
1,200,135
+806,420
+205% +$9.72M 0.05% 270
2019
Q1 		$6.17M Buy
393,715
+197,177
+100% +$3.48M 0.03% 398
2018
Q4 		$3.03M Sell
196,538
-665,164
-77% -$13.6M 0.02% 477
2018
Q3 		$18.6M Buy
861,702
+549,000
+176% +$12.7M 0.08% 205
2018
Q2 		$7.6M Buy
312,702
+301,574
+2,710% +$6.15M 0.03% 330
2018
Q1 		$190K Buy
11,128
+11,009
+9,251% +$215K ﹤0.01% 1069
2017
Q4 		$2K Hold
119
– – ﹤0.01% 1535
2017
Q3 		$2K Sell
119
-44,181
-100% -$994K ﹤0.01% 1372
2017
Q2 		$1.47M Sell
44,300
-43,610
-50% -$1.35M 0.01% 639
2017
Q1 		$2.82M Sell
87,910
-106,833
-55% -$3.65M 0.01% 536
2016
Q4 		$7.06M Sell
194,743
-23,039
-11% -$920K 0.03% 347
2016
Q3 		$10M Sell
217,782
-9,690
-4% -$506K 0.05% 273
2016
Q2 		$11.4M Sell
227,472
-73,367
-24% -$3.91M 0.06% 249
2016
Q1 		$16.1M Sell
300,839
-2,420,076
-89% -$142M 0.08% 225
2015
Q4 		$179M Sell
2,720,915
-1,467,613
-35% -$90.7M 0.93% 20
2015
Q3 		$236M Sell
4,188,528
-402,939
-9% -$26.1M 1.29% 11
2015
Q2 		$271M Buy
4,591,467
+912,758
+25% +$56.3M 1.32% 12
2015
Q1 		$229M Sell
3,678,709
-893,344
-20% -$51.9M 1.06% 20
2014
Q4 		$263M Buy
4,572,053
+482,591
+12% +$26.9M 1.17% 15
2014
Q3 		$220M Buy
4,089,462
+1,254,122
+44% +$66.4M 1.06% 19
2014
Q2 		$149M Buy
2,835,340
+2,377,712
+520% +$122M 0.72% 27
2014
Q1 		$24.2M Buy
457,628
+125,397
+38% +$5.8M 0.13% 161
2013
Q4 		$13.3M Buy
332,231
+74,460
+29% +$2.93M 0.07% 214
2013
Q3 		$9.74M Sell
257,771
-95,054
-27% -$3.71M 0.06% 231
2013
Q2 		$13.8M Buy
+352,825
New +$13.7M 0.1% 176

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management's TEVA Position: Q1 2026 in Review

Acadian Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 390% in Q1 2026, buying an estimated $10.2M and bringing the position to 397,716 shares worth $12M. The position accounts for 0.02% of the portfolio, ranked #488.

Acadian Asset Management first reported a position in TEVA in Q2 2013 and has held it in 46 quarters since. The position peaked at $271M in Q2 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Acadian Asset Management held 397,716 shares of Teva Pharmaceuticals worth $12M as of Q1 2026.
  • Acadian Asset Management bought 316,587 Teva Pharmaceuticals shares in Q1 2026, an estimated $10.2M.
  • Teva Pharmaceuticals made up 0.02% of Acadian Asset Management's portfolio in Q1 2026, its #488 holding.
  • Acadian Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
  • Acadian Asset Management's Teva Pharmaceuticals position peaked at $271M in Q2 2015.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.